JP2020519635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519635A5 JP2020519635A5 JP2019562349A JP2019562349A JP2020519635A5 JP 2020519635 A5 JP2020519635 A5 JP 2020519635A5 JP 2019562349 A JP2019562349 A JP 2019562349A JP 2019562349 A JP2019562349 A JP 2019562349A JP 2020519635 A5 JP2020519635 A5 JP 2020519635A5
- Authority
- JP
- Japan
- Prior art keywords
- gel composition
- group
- composition according
- sorbitan
- sucrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 96
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 claims description 28
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- 235000002639 sodium chloride Nutrition 0.000 claims description 27
- 229930006000 Sucrose Natural products 0.000 claims description 23
- 239000003349 gelling agent Substances 0.000 claims description 23
- 239000005720 sucrose Substances 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 22
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 20
- 239000003960 organic solvent Substances 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 230000009881 electrostatic interaction Effects 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000012456 homogeneous solution Substances 0.000 claims description 5
- 239000002086 nanomaterial Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 4
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 235000011148 calcium chloride Nutrition 0.000 claims description 4
- 229960001747 cinchocaine Drugs 0.000 claims description 4
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims description 4
- 229960004194 lidocaine Drugs 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 235000011147 magnesium chloride Nutrition 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 229960004919 procaine Drugs 0.000 claims description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 4
- 229960002372 tetracaine Drugs 0.000 claims description 4
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 239000011592 zinc chloride Substances 0.000 claims description 4
- 235000005074 zinc chloride Nutrition 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000005538 encapsulation Methods 0.000 claims description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 3
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 3
- 239000012498 ultrapure water Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229940049964 oleate Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 230000009974 thixotropic effect Effects 0.000 claims description 2
- 239000003589 local anesthetic agent Substances 0.000 claims 9
- 239000001488 sodium phosphate Substances 0.000 claims 6
- 229960005015 local anesthetics Drugs 0.000 claims 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims 4
- 235000019799 monosodium phosphate Nutrition 0.000 claims 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 4
- 125000002091 cationic group Chemical group 0.000 claims 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 2
- 235000019800 disodium phosphate Nutrition 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims 2
- 239000002953 phosphate buffered saline Substances 0.000 claims 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- 150000003512 tertiary amines Chemical group 0.000 claims 2
- 239000007863 gel particle Substances 0.000 claims 1
- 238000001338 self-assembly Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 description 64
- 239000003795 chemical substances by application Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 5
- 230000003444 anaesthetic effect Effects 0.000 description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
- -1 Ascorbyl laurat Chemical compound 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 2
- 229960005274 benzocaine Drugs 0.000 description 2
- 229960003150 bupivacaine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022080798A JP2022103299A (ja) | 2017-05-08 | 2022-05-17 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2023014533A JP2023041861A (ja) | 2017-05-08 | 2023-02-02 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2023173522A JP2023168587A (ja) | 2017-05-08 | 2023-10-05 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502872P | 2017-05-08 | 2017-05-08 | |
| US62/502,872 | 2017-05-08 | ||
| PCT/US2018/031654 WO2018208822A1 (en) | 2017-05-08 | 2018-05-08 | Formulation of nanostructured gels for increased agent loading and adhesion |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022080798A Division JP2022103299A (ja) | 2017-05-08 | 2022-05-17 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020519635A JP2020519635A (ja) | 2020-07-02 |
| JP2020519635A5 true JP2020519635A5 (https=) | 2021-05-27 |
| JP7211974B2 JP7211974B2 (ja) | 2023-01-24 |
Family
ID=62223333
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019562349A Active JP7211974B2 (ja) | 2017-05-08 | 2018-05-08 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2022080798A Pending JP2022103299A (ja) | 2017-05-08 | 2022-05-17 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2023014533A Pending JP2023041861A (ja) | 2017-05-08 | 2023-02-02 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2023173522A Pending JP2023168587A (ja) | 2017-05-08 | 2023-10-05 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022080798A Pending JP2022103299A (ja) | 2017-05-08 | 2022-05-17 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2023014533A Pending JP2023041861A (ja) | 2017-05-08 | 2023-02-02 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2023173522A Pending JP2023168587A (ja) | 2017-05-08 | 2023-10-05 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10881745B2 (https=) |
| EP (1) | EP3621594A1 (https=) |
| JP (4) | JP7211974B2 (https=) |
| AU (2) | AU2018266131B2 (https=) |
| CA (1) | CA3061480A1 (https=) |
| WO (1) | WO2018208822A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3136635A1 (en) * | 2019-04-11 | 2020-10-15 | Convatec Technologies Inc. | Superporous hydrogels, methods of making the same, and articles incorporating the same |
| CN111781128B (zh) * | 2020-06-15 | 2023-07-07 | 迪瑞医疗科技股份有限公司 | 一种尿分析仪用鞘液及其制备方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2417494A1 (fr) | 1978-02-16 | 1979-09-14 | Bottu | Nouvelles compositions analgesiques et antipyretiques contenant un derive de paracetamol |
| AU653026B2 (en) | 1991-06-07 | 1994-09-15 | Teikoku Seiyaku Kabushiki Kaisha | Physiologically active polypeptide-containing pharmaceutical composition |
| GB9403857D0 (en) | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
| JP3439481B2 (ja) * | 1995-11-15 | 2003-08-25 | 生化学工業株式会社 | 光架橋ヒアルロン酸ゲルおよびその製造法 |
| CA2212300A1 (en) | 1997-08-04 | 1999-02-04 | Abdellatif Chenite | In vitro or in vivo gelfying chitosan and therapeutic uses thereof |
| BE1011899A6 (fr) | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
| FR2794998B1 (fr) | 1999-06-21 | 2001-07-27 | Oreal | Organogels et leurs utilisations notamment cosmetiques |
| WO2003006043A1 (en) | 2001-07-10 | 2003-01-23 | Massachusetts Institute Of Technology | Surfactant peptide nanostructures, and uses thereof |
| US20050084470A1 (en) | 2003-10-15 | 2005-04-21 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Skin care and cleansing compositions containing oil seed product |
| CA2544814C (en) | 2003-11-12 | 2013-05-14 | Applied Nanosystems B.V. | Non-symmetrical gelling agent |
| ES2380340T3 (es) | 2003-12-05 | 2012-05-10 | Northwestern University | Anfífilos peptídicos auto-ensamblantes y métodos relacionados para la administración de factores de crecimiento |
| US7410950B2 (en) * | 2004-04-01 | 2008-08-12 | Board Of Regents, The University Of Texas System | Peptides of CaV2.2 that inhibit pain |
| EP1750671B1 (en) | 2004-06-03 | 2008-10-15 | Bracco Research S.A. | Liposomal assembly for therapeutic and/or diagnostic use |
| FR2871701B1 (fr) | 2004-06-21 | 2006-09-22 | Centre Nat Rech Scient Cnrse | Biomateriaux bioactifs pour le relarguage controle de principes actifs |
| US7854943B2 (en) * | 2004-06-24 | 2010-12-21 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| EP1800694A1 (en) | 2005-12-23 | 2007-06-27 | Applied NanoSystems B.V. | Controlled release gels |
| EP1991688B1 (en) | 2006-02-10 | 2019-05-01 | DuPont Tate & Lyle Bio Products Company, LLC | Biodegradable compositions comprising renewably-based, biodegradable 1.3-propanediol |
| EP1991515A4 (en) * | 2006-02-10 | 2013-03-06 | Dupont Tate & Lyle Bio Products Company Llc | BIOLOGICAL SOURCE AND ITS CONJUGATES AS NATURAL AND NON-BREATHING SOLVENTS FOR BIOMASS EXTRACTS, SCENT CONCENTRATES AND OILS |
| US8968784B2 (en) | 2006-05-22 | 2015-03-03 | Research Foundation Of The City University Of New York | Method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery |
| US20080021068A1 (en) * | 2006-07-24 | 2008-01-24 | Akorn, Inc. | Aqueous gel formulation and method for inducing topical anesthesia |
| JP5358574B2 (ja) * | 2007-08-17 | 2013-12-04 | アルション セラピューティクス， インコーポレイテッド | 高濃度の局所麻酔薬調合物 |
| WO2009029543A1 (en) | 2007-08-24 | 2009-03-05 | Aegis Therapeutics, Llc | Controlled release formulations |
| US20090263489A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation |
| WO2010033726A2 (en) | 2008-09-17 | 2010-03-25 | The Brigham And Women's Hospital, Inc. | Drug delivery composition comprising a self-assembled gelator |
| JP5724108B2 (ja) * | 2009-04-22 | 2015-05-27 | メドスキン ソリューションズ ドクター ズベラック アーゲーＭｅｄＳｋｉｎ Ｓｏｌｕｔｉｏｎｓ Ｄｒ．Ｓｕｗｅｌａｃｋ ＡＧ | 凍結乾燥組成物 |
| AU2015200633A1 (en) * | 2009-05-04 | 2015-02-26 | Zars Pharma, Inc. | Methods for treating pains associated with neuroma, nerve entrapment, and other conditions |
| CA2770490C (en) * | 2009-08-11 | 2024-04-16 | The Johns Hopkins University | Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products |
| CN102834096A (zh) * | 2010-01-14 | 2012-12-19 | 卢福研究公司 | 用于疼痛控制的固态成型局部麻醉制剂 |
| EP2361640A1 (en) | 2010-02-25 | 2011-08-31 | Université de Liège | Cell cultivation in chitosan alginate hydrogel beads |
| MX2012011261A (es) * | 2010-04-01 | 2012-12-05 | Pharmanest Ab | Composiciones bioadhesivas de anestesicos locales. |
| JP2013540757A (ja) | 2010-09-24 | 2013-11-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル |
| GB201020193D0 (en) | 2010-11-29 | 2011-01-12 | Biotec Pharmacon Asa | Glucan compositions |
| ES2390428B1 (es) * | 2011-04-15 | 2013-10-01 | Universidad De Almería | Preparado de bacterias probióticas para su administración oral a peces cultivados basado en la encapsulación en hidrogeles de alginato. |
| CN104582826B (zh) | 2012-06-25 | 2018-06-05 | 日产化学工业株式会社 | 分散液及水凝胶形成方法 |
| EP2968109A2 (en) | 2012-09-14 | 2016-01-20 | Cipla Limited | Topical pharmaceutical composition comprising tenofovir, an antibacterial agent and, optonally ciclopirox |
| EP2928513B1 (en) | 2012-12-07 | 2018-06-06 | Kansas State University Research Foundation | Peptide-albumin hydrogel properties and its applications |
| EP2968135A4 (en) | 2013-03-14 | 2016-10-26 | Massachusetts Inst Technology | INJECTABLE, MULTILAYER, SELF-COMPOSITE PEPTIDE RUBBER HYDROGELS FOR LONG-TERM AND DELAYED RELEASE OF HUMAN ANTIBODIES |
| US9789073B2 (en) * | 2013-03-14 | 2017-10-17 | Pathak Holdings, Llc | Compositions, methods and devices for local drug delivery |
| US20150297731A1 (en) * | 2014-04-21 | 2015-10-22 | National Yang-Ming University | Thermosensitive injectable glaucoma drug carrier gel and the fabricating method thereof |
| US9452178B1 (en) * | 2014-10-22 | 2016-09-27 | SatisPharma, LLC | Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations |
| US20170360912A1 (en) * | 2014-12-17 | 2017-12-21 | Socovar, L.P. | Chitosan-based hydrogel and applications thereof. |
| EP4279064A3 (en) * | 2015-05-12 | 2024-02-28 | Incept, LLC | Drug delivery from hydrogels |
| EP3359128A1 (en) | 2015-10-08 | 2018-08-15 | The Brigham and Women's Hospital, Inc. | Stabilized assembled nanostructures for delivery of encapsulated agents |
| US20170319500A1 (en) | 2016-05-06 | 2017-11-09 | The Brigham And Women's Hospital, Inc. | Self-assembled gels for controlled delivery of biologics and labile agents |
| US10568840B2 (en) | 2016-05-06 | 2020-02-25 | The Brigham And Women's Hospital, Inc. | Self assembled gels for controlled delivery of encapsulated agents to cartilage |
| US20180050055A1 (en) * | 2016-08-16 | 2018-02-22 | Hafiz Ahmed | Exploiting nutrient deprivation for modulation of glycosylation - research diagnostic, therapeutic, and biotechnology applications |
| EP3335695B1 (en) * | 2016-12-15 | 2020-02-05 | UPM-Kymmene Corporation | A method for freeze-drying hydrogel comprising nanofibrillar cellulose, a freeze-dried medical hydrogel comprising nanofibrillar cellulose, and a hydrogel comprising nanofibrillar cellulose |
-
2018
- 2018-05-08 EP EP18726703.4A patent/EP3621594A1/en not_active Withdrawn
- 2018-05-08 US US15/974,535 patent/US10881745B2/en not_active Expired - Fee Related
- 2018-05-08 AU AU2018266131A patent/AU2018266131B2/en not_active Ceased
- 2018-05-08 WO PCT/US2018/031654 patent/WO2018208822A1/en not_active Ceased
- 2018-05-08 CA CA3061480A patent/CA3061480A1/en active Pending
- 2018-05-08 JP JP2019562349A patent/JP7211974B2/ja active Active
-
2020
- 2020-12-30 US US17/137,931 patent/US20210196836A1/en not_active Abandoned
-
2021
- 2021-09-28 AU AU2021240143A patent/AU2021240143B2/en not_active Expired - Fee Related
-
2022
- 2022-05-17 JP JP2022080798A patent/JP2022103299A/ja active Pending
-
2023
- 2023-02-02 JP JP2023014533A patent/JP2023041861A/ja active Pending
- 2023-10-05 JP JP2023173522A patent/JP2023168587A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1162148C (zh) | 含有纤维素醚的热凝胶药物转运载体 | |
| CN105597146A (zh) | 伤口愈合用多功能温敏凝胶复合物敷料及其制备与使用方法 | |
| CN111447920A (zh) | 具有高活性物质负载量的口服薄膜 | |
| EP2892564A1 (en) | Hyaluronic acid-based drug delivery systems | |
| RU2016151163A (ru) | Композиции, включающие электрогидродинамически полученные волокна, для нанесения заданных доз активного вещества на кожу или слизистую оболочку | |
| CN104888224A (zh) | 一种两亲性多糖衍生物/泊洛沙姆温敏型原位水凝胶及其制备方法 | |
| RU2018109496A (ru) | Фармацевтическая композиция, содержащая электрогидродинамически полученные волокна, композиция, имеющая улучшенное время удержания в месте применения | |
| CN103491961B (zh) | 阿立哌唑组合物和用于其经皮给药的方法 | |
| CN104254341B (zh) | 药剂缓释载体 | |
| CN104136012A (zh) | 制备装载有活性物质的纳米颗粒的方法 | |
| CN114983930B (zh) | 基于高分子聚合物的ros响应型脑靶向纳米凝胶双层释药系统及其制备方法和应用 | |
| CN108721207A (zh) | 氨基化泊洛沙姆衍生物温度敏感型即型凝胶剂及其制备方法 | |
| JP2021520352A5 (https=) | ||
| KR20170106460A (ko) | 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제 | |
| CN110638752A (zh) | 注射剂 | |
| JP2015515968A5 (https=) | ||
| CN106693042B (zh) | 一种抗菌水凝胶敷料及制备方法 | |
| JP2020519635A5 (https=) | ||
| JP2023168587A (ja) | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 | |
| KR101723724B1 (ko) | 수분감응성 겔이 도포된 야누스패브릭을 포함하는 구강점막용 또는 경피흡수용 패치 | |
| Milkova et al. | Nanocolloids of indomethacin prepared using sonication and subsequent encapsulation with polysaccharide films | |
| US20100297202A1 (en) | Planar antenna and method of manufacturing the same | |
| WO2015026225A1 (en) | Bilayer hydrocolloid films containing therapeutic agents | |
| JP2016517435A5 (ja) | メロペネム誘導体及びその製造法 | |
| Balamurugan | Chitosan: A perfect polymer used in fabricating gene delivery and novel drug delivery systems |